Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to address the root causes of known genetic misexpression. The company has advanced losmapimod into Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a drug designed to increase fetal hemoglobin expression for the treatment of sickle cell disease and β-thalassemia, into Phase 1 clinical development.